Pembrolizumab (Keytruda) – Cancer Immunotherapy

What is Pembrolizumab?

Pembrolizumab, known as Keytruda, is an immunotherapy drug that targets the PD-1 receptor, helping the immune system recognize and attack cancer cells. It is used in treating lung cancer, melanoma, and other malignancies.

Benefits of Pembrolizumab (Keytruda)

• Boosts immune response: Helps the body fight cancer more effectively.
• Treats multiple cancers: Approved for melanoma, lung cancer, and more.
• Less toxic than chemotherapy: Fewer side effects compared to traditional treatments.
• Long-term survival benefits: Shown to extend life expectancy in some cancers.

Pembrolizumab is administered via IV infusion, typically every 3 to 6 weeks, under medical supervision.